TY - JOUR T1 - Rapidly Fatal Pulmonary Fibrosis in a Patient with Psoriatic Arthritis Treated with Adalimumab JF - The Journal of Rheumatology JO - J Rheumatol SP - 398 LP - 399 DO - 10.3899/jrheum.100641 VL - 38 IS - 2 AU - JUSTINE V. COHEN AU - BRIAN C. CAPELL AU - PAUL A. KINNIRY AU - ALAN L. EPSTEIN Y1 - 2011/02/01 UR - http://www.jrheum.org/content/38/2/398.abstract N2 - To the Editor:Anti-tumor necrosis factor-α (TNF-α) drugs are used with increasing frequency for disorders involving the skin, joints, and gastrointestinal tract. A wide range of adverse effects have been identified among over one million patients treated with this class of drugs1. These include bacterial infections, mycobacterial infections, fungal infections, cutaneous malignancies, exacerbations of congestive heart failure, and autoimmune diseases1,2,3. In addition, anecdotal reports have linked interstitial lung disease (ILD) and pulmonary fibrosis to etanercept4, infliximab5, or adalimumab6,7. Recently, one study reported no clear pattern of causal relationship of treatment with infliximab and hospitalization for ILD in patients with rheumatoid arthritis (RA)8. Another … Address correspondence to Dr. Cohen; E-mail: justine.cohen{at}uphs.upenn.edu ER -